Ionis Pharmaceuticals, Inc. today announced new data to be presented for DAWNZERAtm (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results